BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200914
DTEND;VALUE=DATE:20200917
DTSTAMP:20260515T122757
CREATED:20200629T075629Z
LAST-MODIFIED:20200629T075915Z
UID:26114-1600041600-1600300799@www.pharmajournalist.com
SUMMARY:2nd Annual RAS – Targeted Drug Development – Digital Summit
DESCRIPTION:Via the latest data driven case studies from academic and industry pioneers\, the 2nd RAS Targeted Drug Development Summit (running digitally this year!) will shine a spotlight on optimizing the selectivity and tolerability of your anti-RAS therapies\, exploring novel combination strategies and overcome translational pharmacology challenges to set the stage for the 2nd generation of mutation-targeted RAS modulating therapies yet to come. \n \n\nExplore how to leverage the internal structural biology of RAS mutations in order to produce effective and clinically viable therapies with discussions from E Shaw Research\, The Johns Hopkins University School of Medicine & Hospital for Sick Children\nDeep dive into RAS associated pathways in order to optimize combination therapies with insights from Novartis\, Genentech & Deciphera Oncology\nEvaluate the mechanisms of action and resistance of RAS targets to accelerate target validation and clinical translation with insights fromAbbvie\, PhoreMost & Verastem Oncology\nAdopt novel techniques to successfully target therapeutic vulnerabilities in RAS-driven cancers with lessons learnt from BeiGene\, Genentech\, Revolution Medicines\, Oblique Therapeutics & Aro Biotherapeutics\nExplore the successes and future therapeutic potential of targeting mutation beyond G12C from within the RAS community explored Revolution Medicines\, Francis Crick Institute & MD Anderson Cancer Centre\n\nFollowing the success of RAS-Targeted Drug Discovery Summit in 2019\, we will re-unite the RAS community virtually this coming September with the most comprehensive and definitive conference specifically dedicated to this community. \nJoin 250+ of the leading minds from large pharma\, biotech and academia across the globe who are striving to capitalise on the therapeutic opportunity of targeting RAS through advancing novel mechanisms of action\, improving drug-like properties and accelerating the translation of potent and mutation-targeted 2nd generation RAS targeted therapeutic strategies into human clinical trials.
URL:https://www.pharmajournalist.com/event/2nd-annual-ras-targeted-drug-development-digital-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200915
DTEND;VALUE=DATE:20200919
DTSTAMP:20260515T122757
CREATED:20200818T091000Z
LAST-MODIFIED:20200818T091220Z
UID:26798-1600128000-1600473599@www.pharmajournalist.com
SUMMARY:TIDES: Oligonucleotide & Peptide Therapeutics 2020
DESCRIPTION:The #1 event for oligonucleotide\, peptide\, CRISPR and mRNA therapeutic leaders. Join us for top-notch networking\, high-level industry expert speakers\, innovative company presentations\, interactive scientific poster presentations\, and diverse attendee companies and investors — in a multi-day digital format that you can access from anywhere in the world.
URL:https://www.pharmajournalist.com/event/tides-oligonucleotide-peptide-therapeutics-2020/
LOCATION:100% Virtual
ORGANIZER;CN="Informa Connect":MAILTO:Allison.MacDonald@informa.com
END:VEVENT
END:VCALENDAR